Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Developed by Mithra as the bioequivalent version of Livial® Tibelia® is a complex oral formulation composed of tibolone. Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia® in Liechtenstein and Switzerland.
Lead Product(s): Tibolone
Therapeutic Area: Musculoskeletal Product Name: Tibelia
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Mithra Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 11, 2020